Recommended

Teva close to API business sale
First new IPF treatment in US for a decade
Webinar: Radiopharmaceuticals’ time-to-result challenge
AstraZeneca/Daiichi cancer drug boost
Takeda to move away from cell therapy
GSK appoints new CEO
article

Expert view: Maximising treatment efficacy

0
SHARES

Posted: 23 October 2020 | | No comments yet

As a world-leading drug device combination solutions specialist, our purpose of putting patients first enables us to design and manufacture devices that maximise treatment efficacy.

 

Join our free webinar: Mastering Impurity Profiling: USP’s Evolving Standards and Strategies

The pharmaceutical industry is facing a new era of regulation. This webinar focuses on how to effectively navigate these changes by exploring USP’s new frameworks, analytical tools, and regulatory insights.

Date: 15 Oct | Time: 13:00 BST

REGISTER NOW TO SECURE YOUR SPOT <<<

Can’t attend live? No worries – register to receive the recording post-event.

 

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

Ophthalmic – 0 percent preservatives in the drug, 100 percent eye protection

The use of preservatives can cause side effects to the eye, thus jeopardising adherence to treatments and damaging patients’ eyes. Nemera offers a multi-dose closing tip system, Novelia®, which avoids the need for preservatives in the drug and prevents bacterial contamination over the duration of treatment.

Ear, nose and throat – easy use, easy breathe

The number of drugs delivered through the ear, nose and throat is expanding. Nemera offers various technologies with a full range of metred pumps and valve platforms for regulated and unregulated markets: Advancia®, SP270+ and SP370+, SP27 and SP37. Nemera now also offers a child resistant spray system for oral and nasal sprays, in collaboration with Roy LeClair.

Dermal and transdermal – convenient devices for dermal delivery

Some dermal or transdermal drugs can be very sensitive and need to be delivered at a consistent and precise dosage. Nemera offers high-performance atmospheric or airless delivery devices for prescription and OTC applications: Sof’bag®, Sof’Airless and a wide range of pumps

Parenteral – complex devices, simple patient care

Parenteral drug administration exposes patients and healthcare professionals to many hazards. To provide a complete set of services, Nemera has integrated pharmaceutical drug handling capabilities (ability to assemble a filled primary container with a device). Nemera’s experience in drug delivery devices includes: insulin pens and implanters and safety devices for prefilled syringes.

Inhalation – Nemera, a partner of choice

Over 10 million patients use devices manufactured by Nemera every day. From concept generation to large scale manufacturing, Nemera is the key partner for your inhalation device.

Electronic – know-how and capabilities to answer patients’ needs

Nemera has also developed electronic know-how and capabilities to meet patients’ needs. Nemera brings a wealth of knowledge in development, manufacturing and innovation to electronic devices: e-Novelia®, e-Advancia® and Safe’n’SprayTM wearable systems and a cloud platform

Issue

Related topics

Related organisations

Share via
Share via